Skip to main content
R&G PharmaStudies Co., Ltd. logo

R&G PharmaStudies Co., Ltd. — Investor Relations & Filings

Ticker · 301333 ISIN · CNE100005K44 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 475 across all filing types
Latest filing 2026-04-27 Interim / Quarterly Rep…
Country CN China
Listing Shenzhen Stock Exchange 301333

About R&G PharmaStudies Co., Ltd.

https://www.rg-pharma.com

R&G PharmaStudies Co., Ltd. is a comprehensive Contract Research Organization (CRO) providing full-service clinical research solutions to the global pharmaceutical and biotechnology sectors. The company specializes in managing Phase I through IV clinical trials, offering a broad suite of services including clinical trial operation, site management, medical writing, regulatory affairs, and pharmacovigilance. Additionally, R&G provides specialized expertise in data management and biostatistics, ensuring high-quality data integrity and compliance with international standards such as NMPA, FDA, and EMA. With an extensive network of clinical trial sites and a focus on diverse therapeutic areas, the company facilitates efficient drug development processes. R&G is recognized for its integrated approach to clinical development, supporting clients from early-stage research through to post-marketing surveillance and bioequivalence studies.

Recent filings

Filing Released Lang Actions
2026年一季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled as "2026 年第一季度报告" which translates to "2026 First Quarter Report". It contains detailed financial data including balance sheets, income statements, cash flow statements, and explanations of financial changes for the first quarter of 2026. The document explicitly states it is a quarterly report and includes comprehensive financial statements and analysis. It also mentions that the report is unaudited, which is typical for interim or quarterly reports. The length of the document (over 14,000 characters) and the presence of substantive financial data confirm it is the actual report, not just an announcement or summary. Therefore, the document fits the definition of an Interim / Quarterly Report (IR).
2026-04-27 Chinese
第五届董事会第二十次会议决议公告
Regulatory Filings Classification · 60% confidence The document is an announcement of the board of directors’ resolutions from the company’s fifth board meeting, including approval of the Q1 report and voting tallies by directors. It is not the Q1 report itself (no financial statements included) nor an AGM or shareholder vote, nor changes in board composition. It does not fit any specialized category and serves as a general regulatory announcement of a board meeting outcome. Therefore it is classified as a Regulatory Filing (RNS).
2026-04-27 Chinese
关于持股5%以上股东及特定股东减持股份触及1%的整数倍暨减持计划提前实施完成的公告
Major Shareholding Notification Classification · 100% confidence The document is an announcement regarding the reduction of shareholdings by shareholders holding more than 5% of the company's shares. It details the shareholding changes, the completion of a share reduction plan, and compliance with relevant securities laws and regulations. The document includes specific data on share quantities, percentages, and transaction methods, but it is not a financial report, earnings release, or management discussion. It is a regulatory announcement about shareholding changes by major shareholders, specifically about share reduction plans and their completion. This fits the definition of Major Shareholding Notification (MRQ), which covers notifications of changes in significant share ownership levels crossing thresholds.
2026-04-21 Chinese
中国国际金融股份有限公司关于诺思格（北京）医药科技股份有限公司2025年度持续督导跟踪报告
Regulatory Filings Classification · 95% confidence The document is titled as a "2025年度持续督导跟踪报告" which translates to "2025 Annual Continuous Supervision Follow-up Report" by a sponsor (保荐人) for a company. It details the sponsor's review and supervision activities over the year 2025, including information disclosure review, internal control, fundraising supervision, governance, and regulatory compliance. It also reports on issues found and measures taken, company and shareholder commitments, and regulatory measures imposed on the sponsor. The document is a detailed supervisory report rather than a financial statement or earnings release. It is not an annual report (10-K), audit report, or earnings release. It is a specialized regulatory supervisory report related to sponsor duties and ongoing monitoring. This type of document fits best under Regulatory Filings (RNS) as it is a compliance and supervisory report that does not fit other specific categories and is not a direct financial report or announcement.
2026-04-14 Chinese
中国国际金融股份有限公司关于诺思格（北京）医药科技股份有限公司持续督导保荐总结报告书
Regulatory Filings Classification · 95% confidence The document is titled as a "持续督导保荐总结报告书" which translates to "Continuous Supervision Sponsorship Summary Report" issued by a sponsoring institution (China International Capital Corporation) for a company listed on the Shenzhen Stock Exchange. It details the sponsor's ongoing supervision activities, compliance with regulatory requirements, and the use of raised funds during the continuous supervision period after the IPO. The document includes legal compliance statements, descriptions of supervisory work, and evaluations of the issuer's cooperation and disclosure practices. It is not a full annual or interim financial report, nor is it an announcement of voting results or a proxy statement. It is a regulatory compliance and supervision summary report related to the IPO sponsorship and ongoing monitoring, which fits best under the category of Regulatory Filings (RNS) as it does not match other more specific categories like Annual Report, Capital Update, or Earnings Release. The document length is under 5,000 characters, but it contains substantive content rather than just an announcement of a report publication, so it is not RPA. Therefore, the best classification is Regulatory Filings (RNS).
2026-04-10 Chinese
简式权益变动报告书
Major Shareholding Notification Classification · 100% confidence The document is titled as a "简式权益变动报告书" which translates to a "Simplified Equity Change Report." It details the changes in shareholding by specific shareholders in a listed company, including the number of shares held before and after the transaction, the method of transaction (block trade), and the impact on shareholding percentages. It references relevant securities laws and regulations governing disclosure of equity changes. The document is comprehensive and contains detailed information about the shareholding changes, the shareholders involved, and their control relationships. It is not an announcement of a report publication, nor is it a financial report or earnings release. It is a formal report on changes in major shareholdings, consistent with the definition of "Major Shareholding Notification (Code: MRQ)" which covers notifications of changes in significant share ownership levels crossing thresholds. Therefore, the correct classification is MRQ with high confidence.
2026-04-03 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.